OcluMed sells unapproved eye drops with website claims to treat or prevent cataracts, FDA says.
What happened
FDA reviewed the website oclumed.com in July 2023 and found OcluMed Nutritional/Lubricant Eye Drops offered for sale in the U.S. The site claimed the drops prevent or improve cataracts and included testimonials about cataracts and macular degeneration. FDA determined the product is an unapproved new drug and not generally recognized as safe and effective for those uses.
What FDA found
The company sells OcluMed Eye Drops as a new drug without an FDA-approved application.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)FDA says the product is not generally recognized as safe and effective for its claimed uses, making it a new drug.
section 201(p) of the FD&C Act, 21 U.S.C. 321(p)Website claims and testimonials show the eye drops are intended to prevent, improve, or treat cataracts and other eye conditions.
section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)Introducing the unapproved product into interstate commerce violates the FD&C Act.
sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA asks OcluMed to notify it in writing within fifteen working days of the specific steps taken to correct the violations, including steps to prevent recurrence and related documentation. If corrective action cannot be completed in that time, the company must state the reason for delay and when it will finish.
Who should pay attention
- retailers and online sellers of eye drops
- consumers considering cataract or vision claims
- makers of ophthalmic drops or supplements with drug claims
This is a summary. Read the original letter on fda.gov.